
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 0.70 | 0.70 | 0.00 |
Shares | 99.30 | 99.30 | 0.00 |
Other | 0.01 | 0.01 | 0.00 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 17.87 | 20.15 |
Price to Book | 4.17 | 3.96 |
Price to Sales | 2.33 | 2.37 |
Price to Cash Flow | 15.13 | 16.04 |
Dividend Yield | 1.87 | 1.39 |
5 Years Earnings Growth | 9.91 | 11.62 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 99.63 | 94.78 |
Basic Materials | 0.31 | 1.35 |
Consumer Defensive | 0.04 | 3.33 |
Financial Services | 0.02 | 8.34 |
Number of long holdings: 189
Number of short holdings: 2
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 9.46 | 794.10 | -11.66% | |
UnitedHealth | US91324P1021 | 5.70 | 400.68 | -2.62% | |
J&J | US4781601046 | 5.19 | 154.46 | -1.18% | |
AbbVie | US00287Y1091 | 4.79 | 193.34 | -0.90% | |
Novo Nordisk B | DK0062498333 | 3.63 | 457.8 | +3.05% | |
Roche Holding Participation | CH0012032048 | 3.10 | 271.90 | +0.97% | |
Abbott Labs | US0028241000 | 3.07 | 130.88 | +0.10% | |
Merck&Co | US58933Y1055 | 3.03 | 83.26 | -2.28% | |
Novartis | CH0012005267 | 2.84 | 94.65 | +0.92% | |
AstraZeneca | GB0009895292 | 2.64 | 10,692.0 | +0.79% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Legal General US Index Trust C Acc | 3.21B | 4.50 | 15.58 | 15.55 | ||
Legal General US Index Trust C Dist | 771.02M | 4.51 | 15.59 | 15.55 | ||
Legal General US Index Trust F Acc | 503.43K | -9.59 | 7.85 | 12.97 | ||
Legal General US Index Trust F Dist | 21.28K | -9.57 | 7.84 | 12.97 | ||
Legal General US Index Trust I Acc | 1.45B | 27.16 | 11.15 | 15.07 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review